Gene:
SLC2A4
solute carrier family 2 (facilitated glucose transporter), member 4

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA35879

Details

Cytogenetic Location: chr17 : p13.1 - p13.1
GP mRNA Boundary: chr17 : 7185054 - 7191367
GP Gene Boundary: chr17 : 7175054 - 7194367
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to SLC2A4: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. The pharmacogenomics journal. 2013. Del-Aguila J L, et al. PubMed

LinkOuts

Entrez Gene:
6517
OMIM:
125853
138190
UCSC Genome Browser:
NM_001042
RefSeq RNA:
NM_001042
RefSeq Protein:
NP_001033
RefSeq DNA:
AC_000060
AC_000149
NC_000017
NG_012127
NT_010718
NW_001838403
NW_926584
UniProtKB:
GTR4_HUMAN (P14672)
Q05BQ3_HUMAN (Q05BQ3)
Ensembl:
ENSG00000181856
GenAtlas:
SLC2A4
GeneCard:
SLC2A4
MutDB:
SLC2A4
ALFRED:
LO143052P
HuGE:
SLC2A4
Comparative Toxicogenomics Database:
6517
ModBase:
P14672
HumanCyc Gene:
HS11675
HGNC:
11009

Common Searches